Image Source: American Heart Association Journals The California Institute for Regenerative Medicine (CIRM) recently awarded $4 million to support the development of a one-time gene therapy for desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM), a rare and life-threatening genetic disorder. This preclinical award to Deborah D. Ascheim, MD, and her team at Rejuvenate Bio are … Continue reading CIRM $4 million awarded to support innovative Gene Therapy for Rare Heart Disorder
News
CIRM awards $26 million to boost clinical trials for cancer, heart, and rare diseases
The California Institute for Regenerative Medicine (CIRM) is proud to announce the allocation of $26 million to support clinical research targeting a range of cancers, heart conditions, and rare diseases. This significant funding underscores CIRM’s commitment to advancing innovative stem cell and gene therapy-based treatments through all stages of clinical trial development. This latest round … Continue reading CIRM awards $26 million to boost clinical trials for cancer, heart, and rare diseases
Meet Our New CEO: Jonathan Thomas
We are thrilled to (re)introduce Jonathan Thomas (JT) as the new President and CEO of the California Institute for Regenerative Medicine (CIRM). You can check out the original press release here. We recently sat down with JT –who previously served as Chair of the Independent Citizens’ Oversight Committee (ICOC) as well as interim President and … Continue reading Meet Our New CEO: Jonathan Thomas
CIRM Welcomes Jonathan Thomas as New President and CEO
The California Institute for Regenerative Medicine (CIRM) is excited to announce the appointment of Jonathan “JT” Thomas, PhD, JD, as our new President and CEO. JT brings extensive experience and a deep commitment to our mission. Previously, he served as the Chair of the Independent Citizens' Oversight Committee (ICOC) for 12 years and, most recently, … Continue reading CIRM Welcomes Jonathan Thomas as New President and CEO
Transformative stem cell-based treatment for Cystic Fibrosis Sinusitis
A $6 million grant to Dr. Matthew Porteus and his team at Stanford University to develop an innovative stem cell-based gene correction therapy for chronic sinusitis in Cystic Fibrosis (CF) patients. CF is a common genetic disease that currently lacks a cure, causing patients to spend their lives managing symptoms. Despite significant advancements in CF … Continue reading Transformative stem cell-based treatment for Cystic Fibrosis Sinusitis
Supporting a CAR-T cell trial for kidney cancer
Photo Credit: Allogene Therapeutics. Image of the ALLO-316 allogeneic CAR-T cell therapy. The California Institute for Regenerative Medicine (CIRM) awarded $15 million to Dr. John Le Gall and his team at Allogene Therapeutics. This funding will support the development of ALLO-316, an innovative anti-CD70 CAR-T cell product designed to treat metastatic clear cell renal cell … Continue reading Supporting a CAR-T cell trial for kidney cancer
CIRM’s $31 million boost for cancer and eye disease research
The California Institute for Regenerative Medicine (CIRM) recently approved nearly $31 million in funding, further cementing our commitment to advancing the field of regenerative medicine. This substantial investment aims to drive clinical research targeting various cancers and eye diseases. CIRM’s dedication to fostering innovative treatments is demonstrated through its clinical program, which funds eligible stem … Continue reading CIRM’s $31 million boost for cancer and eye disease research
CIRM awards $25 million for discovery and clinical research, infrastructure programs
Stock image of a researcher The California Institute for Regenerative Medicine (CIRM) has recently approved awarding $25 million to fund multiple projects across discovery research, clinical research, and infrastructure programs.This funding will support 11 projects under CIRM's Foundation Awards Program, which aims to drive rigorous studies addressing critical basic knowledge gaps in the biology of … Continue reading CIRM awards $25 million for discovery and clinical research, infrastructure programs
CIRM approves $2.5 million to establish a Patient Support Program
Hataalii Tiisyatonii Begay (HT) participated in a CIRM-funded clinical trial at UCSF for Artemis-SCID, a condition that can be life-threatening or fatal. Photo courtesy Barbara Ries / UCSF. The California Institute for Regenerative Medicine (CIRM) funds innovative cell and gene therapy research and educational programs to advance regenerative medicine in the Golden State. Just as … Continue reading CIRM approves $2.5 million to establish a Patient Support Program
CIRM celebrates landmark 100+ clinical trial awards
Photo credit: Barbara Ries for UCSF, Jaquell Chandler, and OHSU/Christine Torres Hicks The California Institute for Regenerative Medicine (CIRM), California’s Stem Cell Agency and the world’s largest institution dedicated to regenerative medicine reached a milestone when it approved funding for its 100th clinical trial. At the February Independent Citizens’ Oversight Committee (ICOC) meeting, the board … Continue reading CIRM celebrates landmark 100+ clinical trial awards
The Stem Cellar 